SABSW
HealthcareSAB Biotherapeutics, Inc.
Biotechnology
$0.02-1.09%
Key events (≥5% daily moves)
Up dayDown day
About This Company
SAB Biotherapeutics is a biotechnology company focused on creating new treatments that use the body's immune system to fight various illnesses. They are developing medicines for infectious diseases like the flu and MERS-CoV, as well as for autoimmune conditions such as Type 1 diabetes, and even cancer. Their goal is to harness the power of the immune system to offer better health solutions.
http://www.sabbiotherapeutics.comKey Statistics
Open$0.02
Day High$0.02
Day Low$0.02
Prev. Close$0.02
52-Week High$0.05
52-Week Low$0.02
Market Cap$144.33K
Volume16.72K
Avg. Volume—
P/E Ratio—
EPS—
Beta0.61
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
63
Country
US
IPO Date
2021-10-25
Exchange
NASDAQ
52-Week Range
$0.02
52W Low
$0.02
Current
$0.05
52W High
Catalysts & Risks
Catalysts
- ▲Positive clinical trial results for lead therapeutic candidates, such as SAB-185 or SAB-176.
- ▲Successful regulatory approval or Emergency Use Authorization (EUA) for any of their drug candidates.
- ▲New partnerships or collaborations with larger pharmaceutical companies for development or commercialization.
- ▲Expansion of their DiversitAb platform into new disease areas or indications, demonstrating broader applicability.
Risks
- ▼Failure of clinical trials to meet primary or secondary endpoints, leading to delays or discontinuation.
- ▼Intense competition from other biotechnology and pharmaceutical companies developing similar therapeutics.
- ▼Regulatory hurdles or rejections from health authorities, impacting approval timelines or market access.
- ▼Dependence on a limited number of drug candidates, making the company highly susceptible to individual program failures.
AI-generated · For informational use only